Osimertinib mesylate

Osimertinib mesylate is an oral, third-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor, used to treat EGFR advanced non-small cell lung cancer (NSCLC) with positive gene mutations. As a first-line treatment option, osimertinib/Osimertinib is mainly used to treat patients with Del19, L858R or T790Metc. EGFR mutated NSCLC patients. It interferes with the growth, proliferation and survival of tumor cells by inhibiting the activity of EGFR, thereby inhibiting tumor development and metastasis. Osimertinib mesylate/Osimertinib has been clinically proven to have significant efficacy, extending patients' progression-free survival and overall survival, and improving patients' quality of life.